Biotech | April 25, 2022
Shilpa Medicare receives NoC for biosimilar Aflibercept
Aflibercept is the second biosimilar product that has entered the clinical trial phase after biosimilar Adalimumab
Aflibercept is the second biosimilar product that has entered the clinical trial phase after biosimilar Adalimumab
The Phase 3 trial will be conducted under the auspices of the first Regenerative Medicine Advanced Therapy (RMAT) designation approved by the USFDA for an EV therapeutic
Company has invested $150 million to build a 150,000 square-foot commercial manufacturing facility in Research Triangle Park (RTP), North Carolina
Support for biologics manufacturability and Industry 4.0 initiatives
New kit enhances menu of FFPE solutions and allows oncology researchers to extract higher yields of concentrated DNA compared to traditional techniques
The life sciences and pharmaceutical sectors suffer from hard-to-source biological materials, which translates into high costs in research and development
Under the terms of the partnership agreement, Comera will develop a differentiated formulation of an Intas product using Comera's innovative proprietary SQore formulation platform
Marks the second of three biosimilars Amneal expects to receive U.S. approval for in 2022
An RMAT confers eligibility for accelerated approval and priority review of biologics licensing applications (BLA)
Pharmapack trends are a key barometer of global device and packing opportunities in 2022
Subscribe To Our Newsletter & Stay Updated
